Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $1014.59 which represents a decrease of $-25.68 or -2.47% from the prior close of $1040.27. The stock opened at $1037.5 and ...
Currently trading with a volume of 421,493, the REGN's price is down by 0.0%, now at $1040.27. RSI readings suggest the stock ...
Regeneron Pharmaceuticals, a biotechnology firm based in Tarrytown, New York, has purchased the former Quad Graphics printing facility in Saratoga Springs for an undisclosed sum. “This acquisition ...
Discover the top biotech companies pioneering the next healthcare breakthroughs. Learn how innovative firms are ...
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on ...
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
Zacks.com on MSN4d
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPDSanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...
Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback